Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialSherene Loi, Christos Sotiriou, Carsten Denkert et al.|Annals of Oncology|2014Cited by 1.3k
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trialJonas Bergh, Nils Wilking, Tom Wiklund et al.|The Lancet|2000Cited by 343
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyNils Wilking, Jonas Bergh, Elisabet Lidbrink et al.|Annals of Oncology|2007Cited by 36
Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) → 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial.Heikki Joensuu, for The Finnish Breast Cancer Group, Pirkko Kellokumpu‐Lehtinen et al.|Cancer Research|2009Cited by 8
Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC).Heikki Joensuu, Henrik Lindman, Pirkko Kellokumpu‐Lehtinen et al.|Journal of Clinical Oncology|2010Cited by 6